Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Famitinib in Rare Head and Neck Malignancies
NCT07662681Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and famitinib in head and neck cancer (HNC), soft tissue sarcoma (STS), Malignant Melanoma (MM) and 2 more, sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Number of Participants Experiencing an Adverse Event at 12 months. Started Jul 2026; status: recruiting.
02
Drugs
camrelizumabfamitinib
03
Conditions
head and neck cancer (HNC)soft tissue sarcoma (STS)Malignant Melanoma (MM)adenoid cystic carcinoma (ACC)salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT07662681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662681.